Skip to search formSkip to main contentSkip to account menu

Irinotecan hydrochloride

Known as: Camptothecin 11, camptothecin-11 (CPT-11) [brand name], CPT-11 
The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca… 
National Institutes of Health

Related topics

Related topics

38 relations
10 ML irinotecan hydrochloride liposome 4.3 MG/ML Injection [Onivyde]ApoptosisCYP3A7 protein, humanColonic Neoplasms

Narrower (1)

Camptosar

Broader (1)

irinotecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
BACKGROUND The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a… 
Highly Cited
2005
Highly Cited
2005
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
Highly Cited
2003
Highly Cited
2003
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
Promising preclinical activity with agents blocking the function of vascular endothelial growth factor (VEGF) has been observed… 
Highly Cited
2002
Highly Cited
2002
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.
PURPOSE To develop a semimechanistic pharmacokinetic-pharmacodynamic model describing chemotherapy-induced myelosuppression… 
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100… 
Highly Cited
1996
Highly Cited
1996
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
PURPOSE To determine the response rate, survival, and toxicity of the new anticancer agent, irinotecan (CPT-11), in the treatment… 
Highly Cited
1993
Highly Cited
1993
Phase I and pharmacokinetic trial of weekly CPT-11.
PURPOSE We conducted a phase I and pharmacokinetic trial of CPT-11 (irinotecan) to characterize the maximum-tolerated dose (MTD… 
Highly Cited
1992
Highly Cited
1992
CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
PURPOSE To evaluate the activity of CPT-11, which is a new derivative of camptothecin, against refractory or relapsed small-cell… 
Highly Cited
1991
Highly Cited
1991
Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer.
7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) is a novel camptothecin derivative that has been… 
Highly Cited
1990
Highly Cited
1990
Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
DNA topoisomerase I (topo I) has been identified as a principal target of a plant alkaloid camptothecin (CPT) and its derivative… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)